How does Survodutide work?
GLP-1 + glucagon dual agonist (no GIP). Different combination than Retatrutide, pairs satiety with thermogenesis, skipping the GIP arm. In plain terms, Survodutide is a weight-loss drug built for a stronger fat-burn signal than GLP-1-only options. A dual agonist (GLP-1 + glucagon) from Boehringer Ingelheim / Zealand Pharma, where glucagon activation boosts metabolic rate. Mechanistic detail like this comes largely from preclinical and early research, the human picture is limited.
What people use it for
- Users plateaued on GLP-1-only drugs
- People targeting >15% body weight loss
- Phase 2 / 3 trial-followers wanting cutting-edge
References
- Survodutide for treatment of obesity, Phase 2 trial — le Roux CW et al., Lancet Diabetes Endocrinol, 2024
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis — Sanyal et al., N Engl J Med, 2024
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Survodutide
Last updated 2026-06-06.